Heidi Rehm interview
We are now more than a decade into precision oncology medicine. While we could demonstrate success, we are still struggling with not curing enough patients from devastating cancers.
Revolutionizing Precision Oncology: ADCs and n-of-1 Trials at PMWC Jan. 24-26 (Healthcare Professional)
We are now more than a decade into precision oncology medicine. While we could demonstrate success, we are still struggling with not curing enough patients from devastating cancers.
Note from Laura van’t Veer: Join us at PMWC 2024 to explore the Clinical Utilities of Liquid Biopsy (Healthcare Professional)
As the Clinical Utilities of Liquid Biopsies track chair at the Precision Medicine World Conference (PMWC) 2024 Silicon Valley, I am excited to invite you to join us for this enlightening January 24-26 program.
Join Peter Marks (FDA) & Yael Weiss at PMWC: Pioneering the Next Era of Gene Therapies in Rare Diseases
Gene therapy has seen tremendous progress over the past several years with now over a dozen gene therapies approved in the United States and with a robust global pipeline in the works.
Healthcare Professional, Dive into the AI Revolution: Insights from insitro’s CEO Daphne Koller at PMWC 2024
We recently engaged in a discussion with Daphne Koller, CEO and founder of insitro and keynote speaker for the AI & Data Science Track at the PMWC 2024, and will explore opportunities and advancements that are emerging through the intersection of AI and data science.
It’s (still) a Man’s World
Although the health of women has generally seen some improvements over the years, it is still insufficiently supported when it comes to clinical study representation in funding research and in drug development. Women’s health as a medical specialty should include a comprehensive slate of physical, mental, and social well-being and not just focus narrowly on the absence of disease.
Why Can’t we Reach a Consensus on Pharmacogenomic Testing? It’s Absolutely Needed (Howard Maibach)
The lack of specific guidelines on how to adjust medications based on genetic test results, and the difficulty in translating genetic test results into actionable prescribing decisions for affected drugs are the main reasons for the slow adoption of pharmacogenomic testing in the clinical setting.
New Monoclonal Antibody Drugs Slow Alzheimer’s Disease Progression – Leqembi & Donanemab (Healthcare Professional)
We are thrilled to share some groundbreaking developments in the field of precision medicine with you. Two promising new drug candidates, Leqembi and Donanemab, have shown great potential in slowing the progression of Alzheimer’s disease, marking a significant step forward in tackling this challenging condition.
Precision Medicine: Riding the Wave of ChatGPT- PMWC Jan. 24-26, 2024 SAVE THE DATE
At PMWC 2024, we will explore how ChatGPT and similar LLMs can unlock the full potential of precision medicine. Together, we will address the challenges associated with implementation, including ensuring up-to-date content, incorporating human oversight, mitigating potential data biases, and ensuring compliance with the Health Insurance Portability and Accountability Act (HIPAA).
Letter from Vice Chancellor Keith Yamamoto – Public-Private Collaboratives: Essential Elements of Precision Medicine
“Achieving precision medicine depends on federal resources to de-risk bold development, prototype impactful technologies, advance manufacturing, and put public good and public health on solid economic ground.” “Science the Endless Frontier”, the 1945 report prepared for President Roosevelt by Vannevar Bush, established the U.S. science policy framework that stands to this day: the federal government […]
